Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago - 2Pick Your #1 Sort Of Espresso
- 3Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 4Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- 5The Most Important Crossroads in Olympic History
- Air Force made critical errors during October 7 massacre, investigator says
- NASA releases new photos of interstellar comet 3I/ATLAS
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- Green Inflections: A Manual for Inside Plants
- EU foreign ministers commemorate Russian massacre in Bucha
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- The Best Internet based Courses for Expertise Improvement
